Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes

Italian Journal of Neurological Sciences

Volumn 20, Issue 4, 1999, Pages 223-229

  Federico, F ^a   Simone, I L ^a   Lucivero, V ^a   Mezzapesa, D M ^a   De Mari, M ^a   Lamberti, P ^a   Petruzzellis, M ^a   Ferrari, E ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Parkinsonian syndromes; Proton spectroscopy

Indexed keywords

ASPARTIC ACID; CHOLINE; CREATINE; CREATINE PHOSPHATE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; N ACETYLASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; AGED; ARTICLE; BRAIN; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; SHY DRAGER SYNDROME;

ADULT; AGED; ASPARTIC ACID; BRAIN; CHOLINE; CREATINE; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SYSTEM ATROPHY; PARKINSONIAN DISORDERS; PHOSPHOCREATINE; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 0033170086     PISSN: 03920461     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720050035     Document Type: Article

References (40)

1. Colosimo C, Albanese A, Hughes AJ et al (1995) Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease. Arch Neurol 52:294-298
2. Quinn N (1995) Parkinsonism - recognition and differential diagnosis. BMJ 310:447-452
3. Wenning GK, Ben-Shlomo Y, Magalhaes M et al (1995) Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 58:160-166
4. Litvan I, Agid Y, Jankovic J et al (1996) Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (SteeleRichardson-Olszewski syndrome). Neurology 46:922-930
5. Rajput AH, Rozdilsky B, Rajput A (1991) Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sei 18:275-278
6. Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
7. Albanese A, Colosimo C, Bentivoglio AR et al (1995) Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 59:144-151
8. Litvan I, Mangone ÇA, McKee A et al (1996) Natural history of progressive supranuclear palsy (Steele-RichardsonOlszewski syndrome) and clinical predictors of survival: a Clinicopathological study. J Neurol Neurosurg Psychiatry 61:615-620
9. Kaye JA (1998) Diagnostic challenges in dementia. Neurology 51 :S45
10. Savoiardo M, Girotti F, Strada L et al (1994) Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders. J Neural Transm 42[Suppl]:93-l 10
11. Brooks DJ (1994) PET studies in progressive supranuclear palsy. J Neural Transm 42[Suppl]:119-134
12. Burn DJ, Sawle GV, Brooks DJ (1994) Differential diagnosis of Parkinson's disease, multiple system atrophy, and SteeleRichardson-Olszewski syndrome: discriminant analysis of striatal l8F-dopa PET data. J Neurol Neurosurg Psychiatry 57:278-228
13. Nadler JV, Cooper JR (1972) N-Acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. J Neurochem 19:213-219
14. 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 13:23-31
15. 1H-NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 4:47-52
16. 1H-NMR spectra of human brain in vivo. NMR Biomed 4:201-204
17. Vion-Dury J, Meyerhoff DJ, Cozzone PJ et al (1994) What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy? J Neurology 241:354-371
18. Veech RL (1991) The metabolism of lactate. NMR Biomed 4:53-58
19. Federico F, Simone IL, Lucivero V et al (1998) Prognostic value of proton magnetic resonance spectroscopy in ischémie stroke. Arch Neurol 55:489-494
20. Simone IL, Federico F, Trojano M et al ( 1996) High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. J Neurol Sei 144:182-190
21. 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 64:516-523
22. Federico F, Simone IL, Lucivero V et al (1998) Proton magnetic resonance spectroscopy in primary blepharospasm. Neurology 51:892-895
23. Federico F, Simone IL, Lucivero V et al (1997) Proton magnetic resonance spectroscopy in Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62:239-242
24. Federico F, Simone IL, Lucivero V et al (1997) Proton magnetic resonance spectroscopy in Parkinson's disease and atypical parkinsonian disorders. Mov Disord 12:903-909
25. Holshouser BA, Komu M, Möller HE et al (1995) Localized proton NMR spectroscopy in the striatum of patients with idiopathic Parkinson's disease: a multicentre pilot study. Magn Reson Med 33:589-594
26. Davie ÇA, Wenning GK, Barker GJ et al (1995) Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 37:204-210
27. Bowen BC, Block RE, Sanchez-Ramos J et al (1995) Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. Am J Neuroradiol 16:61-68
28. Davie CA, Pirtosek Z, Barker GJ et al (1995) Magnetic resonance spectroscopic study of parkinsonism related to boxing. J Neurol Neurosurg Psychiatry 58:688-691
29. Tedeschi G, Litvan I, Bonavita S et al (1997) Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain 120:1541-1552
30. Clarke CE, Lowry M, Horsman A (1997) Unchanged basal ganglia N-acetylaspartate and glutamate in idiopathic Parkinson's disease measured by proton magnetic resonance spectroscopy. Mov Disord 12:297-301
31. Chaudhuri KR, Lemmens G, Williams SCR et al (1996) Proton magnetic resonance spectroscopy in untreated and levodopa treated Parkinson's disease patients with motor oscillations. Neurology 46:A457
32. Ellis CM, Lemmens G, Williams SCR et al ( 1997) Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology 49:438-444
33. Davie CA, Barker GJ, Machado C et al (1997) Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 12:767-771
34. Jellinger KA (1995) Neurodegenerative disorders with extrapyramidal features - a neuropathological overview. J Neural Transm 46[Suppl]:33-57
35. Golbe LI, Davis PH (1988) Progressive supranuclear palsy. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Urban & Schwarzenberg, Baltimore Munich, pp 121-130
36. Quinn N (1994) Multiple system atrophy. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworths, London, pp 262-281
37. Golbe LI, Davis PH, Schonberg BS et al (1988) Prevalence and natural history of progressive supranuclear palsy. Neurology 8:1031-1034
38. 1H-NMR spectra of human brain in vivo. NMR Biomed 4:47-52
39. Frahm J, Bruhn H, Gyngell ML et al (1989) Localized H-NMR spectroscopy in different regions of the human brain in vivo: relaxation times and concentrations of cerebral metabolites. Magn Reson Med 11:47-63
40. Lantos PL (1994) The neuropathology of progressive supranuclear palsy. J Neural Transm 42[Suppl]:137-152